The Wall Street Journal: Carl Icahn to go public with his opposition to Cigna-Express Scripts merger

The Wall Street Journal: Carl Icahn to go public with his opposition to Cigna-Express Scripts merger

Carl Icahn is going public with his campaign to scuttle Cigna Corp.’s CI, -0.73%   $54 billion plan to buy Express Scripts Holding Co. ESRX, -0.89%  


The billionaire activist investor plans to send an open letter Tuesday urging fellow Cigna shareholders to vote against the deal, which he calls a “$60 billion folly” carrying a “ridiculous” price tag, according to a draft seen by The Wall Street Journal.


“Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks on several fronts,” Icahn writes.


The Journal previously reported that Icahn bought a sizable Cigna stake, plans to vote against the health insurer’s proposed purchase of the pharmacy-benefit manager and was considering publicly airing his concerns to persuade other shareholders to do the same. His concerns include competitive risk from Amazon.com Inc. AMZN, +1.34%   and indications from the Trump administration that it could limit the manufacturer rebates pharmacy-benefit managers get.


An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:


Facebook to banks: Give us your data, we’ll give you our users.


MoviePass slashes offerings to three films a month.